|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China. CA
Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
4
|
Batlle E and Clevers H: Cancer stem cells
revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adorno-Cruz V, Kibria G, Liu X, Doherty M,
Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M,
et al: Cancer stem cells: Targeting the roots of cancer, seeds of
metastasis, and sources of therapy resistance. Cancer Res.
75:924–929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beck B and Blanpain C: Unravelling cancer
stem cell potential. Nat Rev Cancer. 13:727–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pisco AO, Brock A, Zhou J, Moor A,
Mojtahedi M, Jackson D and Huang S: Non-Darwinian dynamics in
therapy-induced cancer drug resistance. Nat Commun. 4:24672013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu Y, Guo R, Wei J, Zhou Y, Ji W, Liu J,
Zhi X and Zhang J: Effects of PI3K inhibitor NVP-BKM120 on
overcoming drug resistance and eliminating cancer stem cells in
human breast cancer cells. Cell Death Dis. 6:e20202015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pattabiraman DR and Weinberg RA: Tackling
the cancer stem cells-what challenges do they pose? Nat Rev Drug
Discov. 13:497–512. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
MacDonagh L, Gray SG, Breen E, Cuffe S,
Finn SP, O'Byrne KJ and Barr MP: Lung cancer stem cells: The root
of resistance. Cancer Lett. 372:147–156. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bach DH, Long NP, Luu TT, Anh NH, Kwon SW
and Lee SK: The dominant role of forkhead box proteins in cancer.
Int J Mol Sci. 19:E32792018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Laissue P: The forkhead-box family of
transcription factors: Key molecular players in colorectal cancer
pathogenesis. Mol Cancer. 18:52019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
Sterlacci W, Savic S, Fiegl M, Obermann E
and Tzankov A: Putative stem cell markers in non-small-cell lung
cancer: A clini-copathologic characterization. J Thorac Oncol.
9:41–49. 2014. View Article : Google Scholar
|
|
15
|
Curtarelli RB, Gonçalves JM, Dos Santos
LGP, Savi MG, Nör JE, Mezzomo LAM and Rodríguez Cordeiro MM:
Expression of cancer stem cell biomarkers in human head and neck
carcinomas: A systematic review. Stem Cell Rev. 14:769–784. 2018.
View Article : Google Scholar
|
|
16
|
Kartal-Yandim M, Adan-Gokbulut A and Baran
Y: Molecular mechanisms of drug resistance and its reversal in
cancer. Crit Rev Biotechnol. 36:716–726. 2016.
|
|
17
|
Kunjachan S, Rychlik B, Storm G, Kiessling
F and Lammers T: Multidrug resistance: Physiological principles and
nanomedical solutions. Adv Drug Deliv Rev. 65:1852–1865. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fletcher JI, Williams RT, Henderson MJ,
Norris MD and Haber M: ABC transporters as mediators of drug
resistance and contributors to cancer cell biology. Drug Resist
Updat. 26:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grasse S, Lienhard M, Frese S, Kerick M,
Steinbach A, Grimm C, Hussong M, Rolff J, Becker M, Dreher F, et
al: Epigenomic profiling of non-small cell lung cancer xenografts
uncover LRP12 DNA methylation as predictive biomarker for
carboplatin resistance. Genome Med. 10:552018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stone A, Zotenko E, Locke WJ, Korbie D,
Millar EK, Pidsley R, Stirzaker C, Graham P, Trau M, Musgrove EA,
et al: DNA methylation of oestrogen-regulated enhancers defines
endocrine sensitivity in breast cancer. Nat Commun. 6:77582015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Flanagan JM, Wilson A, Koo C, Masrour N,
Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A,
Cunnea P, et al: Platinum-based chemotherapy induces methylation
changes in blood DNA associated with overall survival in patients
with ovarian cancer. Clin Cancer Res. 23:2213–2222. 2017.
View Article : Google Scholar
|
|
23
|
Dharmadhikari AV, Szafranski P,
Kalinichenko VV and Stankiewicz P: Genomic and epigenetic
complexity of the FOXF1 locus in 16q24.1: Implications for
development and disease. Curr Genomics. 16:107–116. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lo PK, Lee JS, Liang X, Han L, Mori T,
Fackler MJ, Sadik H, Argani P, Pandita TK and Sukumar S: Epigenetic
inactivation of the potential tumor suppressor gene FOXF1 in breast
cancer. Cancer Res. 70:6047–6058. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fulford L, Milewski D, Ustiyan V,
Ravishankar N, Cai Y, Le T, Masineni S, Kasper S, Aronow B,
Kalinichenko VV and Kalin TV: The transcription factor FOXF1
promotes prostate cancer by stimulating the mitogen-activated
protein kinase ERK5. Sci Signal. 9:ra482016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Milewski D, Pradhan A, Wang X, Cai Y, Le
T, Turpin B, Kalinichenko VV and Kalin TV: FoxF1 and FoxF2
transcription factors synergistically promote rhabdomyosarcoma
carcinogenesis by repressing transcription of p21Cip1 CDK
inhibitor. Oncogene. 36:850–862. 2017. View Article : Google Scholar :
|
|
27
|
Ran L, Chen Y, Sher J, Wong EWP, Murphy D,
Zhang JQ, Li D, Deniz K, Sirota I, Cao Z, et al: FOXF1 defines the
core-regulatory circuitry in gastrointestinal stromal tumor. Cancer
Discov. 8:234–251. 2018. View Article : Google Scholar
|
|
28
|
Gialmanidis IP, Bravou V, Petrou I, Kourea
H, Mathioudakis A, Lilis I and Papadaki H: Expression of Bmi1,
FoxF1, Nanog, and γ-catenin in relation to hedgehog signaling
pathway in human non-small-cell lung cancer. Lung. 191:511–521.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saito RA, Micke P, Paulsson J, Augsten M,
Peña C, Jönsson P, Botling J, Edlund K, Johansson L, Carlsson P, et
al: Forkhead box F1 regulates tumor-promoting properties of
cancer-associated fibroblasts in lung cancer. Cancer Res.
70:2644–2654. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Toh TB, Lim JJ and Chow EK: Epigenetics in
cancer stem cells. Mol Cancer. 16:292017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Easwaran H, Tsai HC and Baylin SB: Cancer
epigenetics: Tumor heterogeneity, plasticity of stem-like states,
and drug resistance. Mol Cell. 54:716–727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wickström M, Dyberg C, Milosevic J, Einvik
C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool
M, et al: Wnt/β-catenin pathway regulates MGMT gene expression in
cancer and inhibition of Wnt signalling prevents chemore-sistance.
Nat Commun. 6:89042015. View Article : Google Scholar
|
|
33
|
Carnero A, Garcia-Mayea Y, Mir C, Lorente
J, Rubio IT and LLeonart ME: The cancer stem-cell signaling network
and resistance to therapy. Cancer Treat Rev. 49:25–36. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suresh R, Ali S, Ahmad A, Philip PA and
Sarkar FH: The role of cancer stem cells in recurrent and
drug-resistant lung cancer. Adv Exp Med Biol. 890:57–74. 2016.
View Article : Google Scholar
|
|
37
|
Lopez-Ayllon BD, Moncho-Amor V, Abarrategi
A, Ibañez de Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R
and Sastre L: Cancer stem cells and cisplatin-resistant cells
isolated from non-small-lung cancer cell lines constitute related
cell populations. Cancer Med. 3:1099–1111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bora-Singhal N, Perumal D, Nguyen J and
Chellappan S: Gli1-mediated regulation of Sox2 facilitates
self-renewal of stem-like cells and confers resistance to EGFR
inhibitors in non-small cell lung cancer. Neoplasia. 17:538–551.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mahlapuu M, Enerbäck S and Carlsson P:
Haploinsufficiency of the forkhead gene Foxf1, a target for sonic
hedgehog signaling, causes lung and foregut malformations.
Development. 128:2397–2406. 2001.PubMed/NCBI
|
|
40
|
Wei HJ, Nickoloff JA, Chen WH, Liu HY, Lo
WC, Chang YT, Yang PC, Wu CW, Williams DF, Gelovani JG and Deng WP:
FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming
of lung cancer cells. Oncotarget. 5:9514–9529. 2014. View Article : Google Scholar : PubMed/NCBI
|
